PainReform Ltd
PainReform Ltd (PRFX) is a micro‑cap healthcare company (market cap US$2.58m) that describes itself as focused on developing treatments and technologies for managing pain. As a very small, early‑stage issuer it is likely to be pre‑revenue or dependent on research and development, partnerships and regulatory milestones; commercial success is uncertain and may take years. Investors should be aware of high volatility, limited liquidity and the real possibility of dilution from future fundraising. Key drivers include scientific progress, trial results, intellectual property and regulatory approvals; setbacks on any of these fronts can materially affect the share price. This summary is for general educational purposes only and is not personal financial advice. PainReform may suit only experienced, risk‑tolerant investors prepared for potential loss of capital; always carry out further due diligence and consider professional advice where appropriate.
Stock Performance Snapshot
Analyst Rating
Analysts recommend holding PainReform's stock with a target price of $12, indicating potential growth.
Financial Health
PainReform Ltd is generating strong cash flow, indicating a healthy financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring PRFX
Beyond Opioids: The Race For New Painkillers
Vertex Pharmaceuticals has halted the development of its non-opioid painkiller, creating uncertainty but also a potential opening for competitors. This theme focuses on other pharmaceutical companies that could capture market share as they advance their own non-opioid treatments.
Published: August 5, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Early-stage potential
Scientific or clinical progress could create value over time, though timelines are uncertain and success is not guaranteed.
Clinical catalysts
Trial results and regulatory milestones tend to move micro‑cap biotech stocks sharply; both positive and negative outcomes matter.
Liquidity & dilution
Small market capitalisation often means thin trading and a likelihood of future fundraising which can dilute existing holders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
